ZeroHedge News
Follow
Americans Will Foot The Bill For Germany's New Drug Price Controls
Germany is implementing healthcare cost-cutting measures that will likely shift the financial burden onto the United States. These measures involve capping spending growth, restricting care, and demanding steep discounts from drugmakers. Such actions allow Germany to save money, but they do not eliminate the costs of research and development, which drug companies still need to fund. Because other wealthy nations use similar price controls, the US bears a disproportionate share of global drug innovation costs. American patients account for a substantial portion of global pharmaceutical profits despite representing a smaller portion of the global GDP. This situation allows foreign countries to benefit from American medical innovation while paying less for the same treatments. President Trump has been working to end this practice by encouraging other countries to pay fair prices. The US can't implement similar cost-cutting measures without hindering innovation. The only answer is to make other nations pay their fair share and prevent freeloading. The recent deal with the UK shows that the US can achieve positive results. Germany's new plan deepens the financial imbalance further, thus increasing costs in the US market. The US must take a firm stance to address this issue and should investigate drug-pricing policies. Enforcing fair pricing will alleviate pressure on American patients, stop foreign countries from freeloading, and preserve advancements in medicine.
